Near Infrared Spectroscopy in Sickle Cell Pediatric Patients

Overview

Endothelial dysfunction contributes to vaso-occlusion and acute pain in sickle cell disease. Near infrared spectroscopy (NIRS) technology can measure tissue oxygenation and endothelial function. The main objective of this study is to study the natural history of tissue muscle oxygenation using NIRS in pediatric sickle cell subjects experiencing acute pain and pediatric sickle cell patients in steady-state.

Full Title of Study: “Near-infrared Spectroscopy in Sickle Cell Pediatric Patients During Pain Crisis and After Recovery”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 3, 2023

Interventions

  • Diagnostic Test: Near infrared spectroscopy
    • NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.

Arms, Groups and Cohorts

  • Sickle cell pain crisis
  • Sickle cell steady-state

Clinical Trial Outcome Measures

Primary Measures

  • Tissue oxygenation
    • Time Frame: 6 months

Secondary Measures

  • Nitric oxide
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis: 1. Age 6 to 21 years old. 2. Diagnosis of sickle cell anemia: a. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required). 3. Acute onset pain crisis in a distribution typical for that subject, onset within the last 7 days and for which hospitalization and parenteral narcotic pain treatment are required. 4. Ability to provide informed written consent. Exclusion Criteria for Subjects with Sickle Cell Disease in Pain Crisis: 1. Pregnancy. 2. History of non-trivial injury, burns, surgery or skin ulcers on the arms. 3. Fever or suspected sepsis at time of pain crisis 4. Administration of any of the following drugs within the last 14 days:

  • Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) – Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan) – Nitric oxide donors (nitroglycerin, nitroprusside, nitrates) 5. Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment. 6. Diagnosis with any of the following chronic diseases or conditions: – History of high blood pressure – History of high cholesterol – History of diabetes – History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL) – History of coronary artery disease or peripheral vascular disease 7. Received a blood transfusion within 7 days of the study procedure. Inclusion Criteria for Subjects with Sickle Cell Disease in Steady State: 1. Age 6-21 years 2. Diagnosis of sickle cell disease (electrophoresis or HPLC documentation of hemoglobin SS, SC, S-beta-thalassemia or other hemoglobinopathies causing sickle cell disease is required). 3. Ability to provide informed written consent. Exclusion Criteria for Subjects with Sickle Cell Disease in Steady State: 1. Pregnancy. 2. History of non-trivial trauma, burns, surgery or skin ulcers on the arms. 3. Fever or suspected sepsis at time of pain crisis 4. Experience of an acute pain crisis requiring intravenous (IV) narcotics and hospital admission within the last 14 days. 5. Ingestion of caffeine within the 12 hours before the start of the study appointment, or tobacco use within the 30 days before the study appointment. 6. Administration of any of the following drugs within the last 14 days: – Phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) – Endothelin-1 receptor blockers (bosentan, sitaxentan, ambrisentan, tezosentan) – Nitric oxide donors (nitroglycerin, nitroprusside, nitrates) 7. Diagnosis of any of the following chronic diseases or conditions: – History of high blood pressure – History of high cholesterol – History of diabetes – History of chronic kidney disease (serum creatinine must not be greater than 2 mg/dL) – History of coronary artery disease or peripheral vascular disease 8. Received a blood transfusion within 7 days of the study procedure.

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: 21 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s National Research Institute
  • Collaborator
    • National Institute of Allergy and Infectious Diseases (NIAID)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Suvankar Majumdar, Chief of Hematology – Children’s National Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.